Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × Antibodies, Monoclonal × Clear all

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase 1/2 Completed

35 enrolled 11 charts

Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00265928 2008-01-28

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

46 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma.

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma